1.3.1.48: 13,14-dehydro-15-oxoprostaglandin 13-reductase
This is an abbreviated version!
For detailed information about 13,14-dehydro-15-oxoprostaglandin 13-reductase, go to the full flat file.
Word Map on EC 1.3.1.48
-
1.3.1.48
-
eicosanoids
-
15-hydroxyprostaglandins
-
15-pgdh
-
cyclooxygenases
-
acylfulvene
- 1.3.1.48
-
eicosanoids
- 15-hydroxyprostaglandins
- 15-pgdh
-
cyclooxygenases
- acylfulvene
Reaction
Synonyms
15-hydroxyprostaglandin dehydrogenase, 15-keto-PG reductase, 15-ketoprostaglandin DELTA-13-reductase, 15-ketoprostaglandin DELTA13-reductase, 15-ketoprostaglandinDELTA13-reductase, 15-oxoprostaglandin 13-oxidase, 15-oxoprostaglandin 13-reductase, 15-oxoprostaglandin DELTA13-reductase, 15-oxoprostaglandin-DELTA13-reductase, 15-PGDH, Ad-PGR, bifunctional leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase, bifunctional LTB4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase, DELTA13-15-ketoprostaglandin reductase, leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin 13-reductase, leukotriene B4 dehydrogenase, leukotriene B4-12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase, LTB4 12-HD/PGR, LTBDH/PGR, NAD(P)H-dependent alkenal/one oxidoreductase, PG reductase, PGR, PGR-2, PGR1, prostaglandin 13-reductase, prostaglandin DELTA13-reductase, prostaglandin reductase 1, reductase, 15-oxo-DELTA13-prostaglandin
ECTree
1.3.1.48 13,14-dehydro-15-oxoprostaglandin 13-reductaseAdvanced search results
results (
results (Substrates Products
Substrates Products on EC 1.3.1.48 - 13,14-dehydro-15-oxoprostaglandin 13-reductase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
SUBSTRATE 
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(13E)-11alpha-hydroxy-9,15-dioxoprost-13-enoate + NADPH + H+
11alpha-hydroxy-9,15-dioxoprostanoate + NADP+
-
-
-
?
(5S,6R)-dihydroxy-15-oxo-(7E,9E,11Z,13E)-eicosatetraenoic acid + NADH
13,14-dihydro-(5S,6R)-dihydroxy-15-oxo-(7E,9E,11Z)-eicosatetraenoic acid + NAD+
-
trivial name 15-oxo-lipoxin A4
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
(Z)-3-[(5-methoxy-3-oxo-2(3H)-benzofuranylidene)-methyl]benzoic acid + NAD(P)H
3-[(5-methoxy-3-oxo-2,3-dihydro-1-benzofuran-2-yl)methyl]benzoic acid + NAD(P)+
-
-
-
?
1-(p-carboxyphenyl)-5-cyano-3-oxo-1-pentene + NAD(P)H
1-(p-carboxyphenyl)-5-cyano-3-oxo-pentane + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NADPH
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NADP+
-
-
-
-
?
11alpha-hydroxy-9,15-dioxoprostanoate + NAD(P)+
(13E)-11alpha-hydroxy-9,15-dioxoprost-13-enoate + NAD(P)H + H+
-
-
-
?
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E1 + NAD+
-
-
-
-
r
15-ketoprostaglandin E1 + reduced nicotinamide hypoxanthine dinucleotide + H+
13,14-dihydro-15-keto-prostaglandin E1 + nicotinamide hypoxanthine dinucleotide
-
-
-
-
r
15-ketoprostaglandin E2 + NADPH + H+
13,14-dihydro-15-keto-prostaglandin E2 + NADP+
-
-
-
?
15-ketoprostaglandin E2 + reduced nicotinamide hypoxanthine dinucleotide + H+
13,14-dihydro-15-ketoprostaglandin E2 + nicotinamide hypoxanthine dinucleotide
-
93% activity compared to NADH
-
-
r
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
trans-2-(o-hydroxybenzylidene)acetophenone + NAD(P)H
(o-hydroxybenzyl)acetophenone + NAD(P)+
-
-
-
?
trans-2-benzylidenecyclohexan-2-one + NAD(P)H
benzylcyclohexan-2-one + NAD(P)+
-
-
-
?
trans-3-(2-furyl)acrolein + NAD(P)H
2-furylpropanal + NAD(P)+
-
-
-
?
trans-4-furyl-3-buten-2-one + NAD(P)H
4-furyl-butane-2-one + NAD(P)+
-
-
-
?
trans-benzylideneacetophenone + NAD(P)H
benzylacetophenone + NAD(P)+
-
-
-
?
trans-phenyl-1-propenyl ketone + NAD(P)H
phenylpropane-1-one + NAD+
-
-
-
?
(5S,12R)-dihydroxy-(6E,8Z,10Z,14E)-eicosatetraenoic acid + NADH
?
-
15-keto-prostaglandin-13-reductase activity is 200fold higher than leukotrien B4-12hydroxydehydrogenase activity
-
-
?
(5S,12R)-dihydroxy-(6E,8Z,10Z,14E)-eicosatetraenoic acid + NADH
?
-
trivial name leukotriene B4, enzyme exhibits a 15-ketoprostaglandin-13-reductase and a very low leukotriene B4 12-hydroxydehydrogenase activity
-
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
no substrate: prostaglandin E1
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
no substrates: 15-hydroxyprostaglandins, progesterone, cortisone, orotic acid, fumaric acid
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
no substrates: 15-hydroxyprostaglandins, progesterone, cortisone, orotic acid, fumaric acid
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
55% of activity with 15-keto-prostaglandin E2
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
-
?
15-ketoprostaglandin A1 + NAD(P)H
?
-
108% of activity with 15-keto-prostaglandin E2
-
-
?
15-ketoprostaglandin B1 + NAD(P)H
?
-
79% of activity with 15-keto-prostaglandin E2
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-keto-prostaglandin E1 + NAD+
-
-
-
-
r
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-keto-prostaglandin E1 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
100% activity
-
-
r
15-oxoprostaglandin F1alpha + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-oxoprostaglandin F1alpha + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-oxoprostaglandin F1alpha + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
56% of activity with 15-keto-prostaglandin E2
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
i.e. 15-ketoprostaglandin F2alpha
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
i.e. 15-ketoprostaglandin F2alpha
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
i.e. 15-ketoprostaglandin F2alpha
-
?
additional information
?
-
-
essential enzyme for eicosanoid inactivation
-
-
?
additional information
?
-
PGR1, which catalyzes the NADPH-dependent reduction of the alpha,beta-double bond of aliphatic and aromatic aldehydes and ketones, and 15-keto-prostaglandins. PGR1 also shows low activity in the oxidation of leukotriene B4. The best substrates in terms of kcat/Km are 15-keto-prostaglandins, trans-3-nonen-2-one, and trans-2-decenal. Molecular docking simulations, role of Arg56 and Tyr245 in 15-keto-prostaglandin binding, overview
-
-
?
additional information
?
-
-
PGR1, which catalyzes the NADPH-dependent reduction of the alpha,beta-double bond of aliphatic and aromatic aldehydes and ketones, and 15-keto-prostaglandins. PGR1 also shows low activity in the oxidation of leukotriene B4. The best substrates in terms of kcat/Km are 15-keto-prostaglandins, trans-3-nonen-2-one, and trans-2-decenal. Molecular docking simulations, role of Arg56 and Tyr245 in 15-keto-prostaglandin binding, overview
-
-
?
additional information
?
-
not active towards 6-keto-prostaglandin F1alpha, prostaglandin F2beta, 11beta-prostaglandin F2alpha, 13,14-dihydro-15-keto-prostaglandin D2, 13,14-dihydro-15-keto-prostaglandin E2, 13,14-dihydro-15-keto-PGF2alpha, and leukotriene B4
-
-
?
additional information
?
-
bifunctional enzyme capable of inactivating leukotriene B4 and 15-oxo-prostaglandins, enzyme plays a role in growth suppressive functions in lung cancer
-
-
?
